Welcome to our dedicated page for Novelis news (Ticker: NVL), a resource for investors and traders seeking the latest updates and insights on Novelis stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Novelis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Novelis's position in the market.
Novelis announced the launch of a roadshow for its IPO, offering 45,000,000 common shares. The selling shareholder, a subsidiary of Hindalco Industries, may allow underwriters to buy an extra 6,750,000 shares to cover over-allotments. The shares are estimated at $18.00 to $21.00 each. Novelis applied to list on the NYSE under the symbol 'NVL'. Post-IPO, Hindalco's subsidiary will own 92.5% of Novelis (91.4% with over-allotment). Major underwriters include Morgan Stanley and BofA Securities. Novelis will not receive proceeds from this sale.